Effects of glyburide therapy on lipoproteins in non-insulin-dependent diabetes mellitus.
Twenty-seven patients with non-insulin-dependent diabetes mellitus and fasting plasma glucose values greater than 140 mg/dl began glyburide therapy. After entry into the study, patients were classified into three phenotypes on the basis of their initial lipoprotein profile: type IV, mixed, and normal. Glyburide lowered plasma glucose and raised plasma insulin concentrations in non-insulin-dependent diabetes mellitus. Patients with type IV hyperlipoproteinemia had higher fasting free insulin concentrations before and after therapy than patients without hyperlipoproteinemia and may have a slightly reduced hypoglycemic response to glyburide therapy. The drug caused a significant reduction in very-low-density lipoprotein cholesterol in patients with non-insulin-dependent diabetes mellitus and type IV hyperlipoproteinemia, along with a variable change in high-density lipoprotein cholesterol, independent of its effect on plasma glucose.
D002784:Cholesterol / Q000378:metabolism; D015243:Cholesterol, VLDL; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005069:Evaluation Studies as Topic; D005905:Glyburide / Q000627:therapeutic use*; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D008074:Lipoproteins / Q000378:metabolism*; D008079:Lipoproteins, VLDL / Q000378:metabolism; D009765:Obesity / Q000150:complications
D015243:Cholesterol, VLDL; D007328:Insulin; D008074:Lipoproteins; D008079:Lipoproteins, VLDL; D002784:Cholesterol; D005905:Glyburide